Shares of Eleven Biotherapeutics Inc. (EBIO) are set to take a beating on Tuesday, following failure of the company’s phase III clinical trial of its lead drug candidate, Isunakinra (EBI-005), for the treatment of severe allergic conjunctivitis.
Forex – financial instrument.Forex news
Shares of Eleven Biotherapeutics Inc. (EBIO) are set to take a beating on Tuesday, following failure of the company’s phase III clinical trial of its lead drug candidate, Isunakinra (EBI-005), for the treatment of severe allergic conjunctivitis.